The pathobiology of the terminal complement complexes
- PMID: 2650989
- DOI: 10.1159/000463070
The pathobiology of the terminal complement complexes
Abstract
C5b and the other late-acting complement components can assemble the two terminal complexes (TCC) C5b-9 and SC5b-9. In addition to the lytic effects of C5b-9 it has been demonstrated that sublytic amounts of C5b-8 or C5b-9 can stimulate several important cellular activities. These effects may be important to explain the role of C5b-9 in the production and progression of several pathological conditions that has been demonstrated in experimental models of disease. With the help of antibodies that specifically recognize C9 neoantigens, deposits of TCC have been identified in human tissues, not only in immunological diseases but also in certain nonimmunological diseases. In the latter it has been shown that often there is no concordance between deposits of TCC and those of immunoglobulins and C3. Methods for measuring SC5b-9 in biological fluids have also been developed. Normal plasma was found to have low levels of SC5b-9. Increased plasma levels of SC5b-9 have been observed during the active phase of SLE nephritis, in certain infections and during cardiopulmonary bypass. Increased levels were also found in the cerebrospinal fluid of patients with inflammatory diseases of the central nervous system and in the synovial fluid of patients with rheumatoid arthritis. Autoantibodies to C9 neoantigens in plasma of certain patients with autoimmune, infectious or neoplastic diseases have recently been recognized. Additional work is needed to better delineate the potential usefulness of these findings for diagnosis and evaluation of disease activity.
Similar articles
-
Levels of SC5b--9 complement complex in plasma and synovial fluid of patients with rheumatic disease.Med Interne. 1990 Oct-Dec;28(4):305-10. Med Interne. 1990. PMID: 2100875
-
Immunohistochemical detection of the membrane and fluid-phase terminal complement complexes C5b-9(m) and SC5b-9. Consequences for interpretation and terminology.Scand J Immunol. 1987 Oct;26(4):381-6. doi: 10.1111/j.1365-3083.1987.tb02270.x. Scand J Immunol. 1987. PMID: 3685888
-
Immunohistochemical study of the C5b-9 complex of complement in human kidneys.Kidney Int. 1986 Sep;30(3):399-410. doi: 10.1038/ki.1986.198. Kidney Int. 1986. PMID: 3537447
-
[Functions and relevance of the terminal complement sequence].Immun Infekt. 1990 Jun;18(3):71-9. Immun Infekt. 1990. PMID: 2199368 Review. German.
-
Functions and relevance of the terminal complement sequence.Blut. 1990 Jun;60(6):309-18. doi: 10.1007/BF01737843. Blut. 1990. PMID: 2198074 Review.
Cited by
-
Complement inhibition by human vitronectin involves non-heparin binding domains.Clin Exp Immunol. 1995 Jul;101(1):136-41. doi: 10.1111/j.1365-2249.1995.tb02289.x. Clin Exp Immunol. 1995. PMID: 7542572 Free PMC article.
-
Different mechanisms of serum complement activation in the plasma of common (Chelydra serpentina) and alligator (Macrochelys temminckii) snapping turtles.PLoS One. 2019 Jun 6;14(6):e0217626. doi: 10.1371/journal.pone.0217626. eCollection 2019. PLoS One. 2019. PMID: 31170203 Free PMC article.
-
The kinetics and distribution of C9 and SC5b-9 in vivo: effects of complement activation.Clin Exp Immunol. 1995 Apr;100(1):40-6. doi: 10.1111/j.1365-2249.1995.tb03601.x. Clin Exp Immunol. 1995. PMID: 7697921 Free PMC article.
-
Promotion of the inflammatory response in mid colon of complement component 3 knockout mice.Sci Rep. 2022 Feb 1;12(1):1700. doi: 10.1038/s41598-022-05708-8. Sci Rep. 2022. PMID: 35105928 Free PMC article.
-
Detection of the terminal fluid-phase complement complex, SC5b-9, in the plasma of patients with insulin-dependent (type I) diabetes mellitus. Relation to increased urinary albumin excretion and plasma von Willebrand factor.Clin Exp Immunol. 1991 Apr;84(1):53-8. Clin Exp Immunol. 1991. PMID: 2015712 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Research Materials
Miscellaneous